Is There a Prenatal Treatment for XLHED?

Yes, there is currently an experimental prenatal treatment being investigated for X-linked hypohidrotic ectodermal dysplasia (XLHED). This treatment is part of an ongoing clinical study called the EDELIFE trial. It aims to correct a genetic communication error during fetal development, potentially allowing the baby to develop functional sweat glands and teeth before birth.

How the Prenatal Treatment Works

In XLHED, a specific signaling protein called Ectodysplasin A1 (EDA1) is missing or does not work correctly. This protein is essential because it tells the developing fetus to form structures like sweat glands, teeth, and hair ^[1][2]. The experimental treatment uses a manufactured protein called ER004, which is designed to act as a direct replacement for the missing EDA1 protein ^[3][4].

During a critical window of fetal development—typically in the late second and third trimesters—the ER004 protein is delivered directly into the amniotic fluid surrounding the baby using a needle guided by ultrasound ^[5][3]. The treatment usually involves a series of injections (often 2 to 3) rather than a single dose. The baby naturally swallows the amniotic fluid, allowing the replacement protein to reach the developing tissues and send the signals needed to grow sweat glands and teeth ^[3][6].

What Are the Potential Benefits?

Early cases where this treatment was used under “compassionate use” (a regulatory pathway allowing access to experimental treatments outside of a formal trial for serious conditions) have shown promising results. When administered before birth, the replacement protein has been shown to:

• Restore sweating ability: Treated children have successfully developed functional sweat glands, allowing them to sweat and safely regulate their body temperature ^[3][7]. Follow-up studies indicate this sweating ability persists long-term, with positive results seen up to 6 years of age ^[8][7].
• Improve tooth development: Infants treated before birth developed a higher number of permanent teeth compared to affected family members who did not receive the treatment ^[8].
• Improve overall development: Animal studies suggest that replacing the missing protein early may also help correct other developmental issues related to XLHED, such as certain bone development problems ^[9][10].

While the ER004 protein itself has not shown a harmful immune response in babies or negative chemical impacts on pregnant mothers, it is crucial to understand that the delivery method carries risks ^[4]. The ultrasound-guided injection into the amniotic fluid is similar to an amniocentesis and carries standard obstetric procedural risks, including the potential for premature labor, amniotic fluid leakage, or infection.

The EDELIFE Clinical Trial

The EDELIFE trial (ClinicalTrials.gov identifier: NCT04590547) is a multicenter clinical study actively evaluating the safety and effectiveness of using ER004 as a prenatal treatment ^[3][11]. The trial focuses specifically on male fetuses because XLHED is an X-linked genetic condition, meaning males are predominantly and more severely affected ^[3].

Because this treatment must be given during a precise developmental window, early screening and genetic testing are essential for expecting parents with a known family history of ectodermal dysplasia ^[3][12].

• First Trimester: A definitive diagnosis of XLHED relies on early genetic testing (such as Chorionic Villus Sampling or amniocentesis) to identify the specific genetic mutation in the EDA gene ^[3][12].
• Second Trimester (Weeks 20-24): To determine if a fetus is eligible for the trial, doctors perform a specialized ultrasound to check for the presence of developing tooth buds (tooth germs) in the baby’s jaw ^[11]. Finding fewer than six tooth buds confirms the physical signs of the condition and establishes eligibility for the study ^[11].